HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Partnered Content
Report Store
UsernamePublicRestriction
Tags:
Health OTC Drugs Ad Campaigns

HRA Pharma Targets ‘Life Enthusiasts’ In The UK With New Compeed Campaign

  • News

Executive Summary

HRA Pharma targets active consumers in its new £2.5m multi-channel UK marketing campaign for recently acquired popular foot-care brand, Compeed.

You may also be interested in...



HRA Pharma Expands Footprint With Middle East Move

France's HRA is looking to tap into consumer demand for foot care products in the Middle East by rolling out its Compeed brand in select markets across the region.

Can You Kick It? Yes You Can, With Six New Foot-Care Products In The UK

New OTC medicines for fungal nail infections and verrucas have been launched in the UK by Galderma, Reckitt Benckiser and Vemedia, while new foot-care products have also been introduced by Blistex, Epitact and Dermatonics.

HRA Pharma Breaks Into US Consumer Health Market With Mederma Acquisition

EllaOne and Compeed manufacturer HRA Pharma is set to establish a notable presence in the US consumer health market by acquiring the Mederma dermatology range from Germany's Merz.

Table

View full table

Related Content

HBW Insight

Topics

Related Companies

Tags:
Health OTC Drugs Ad Campaigns
UsernamePublicRestriction

Register

LL005491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By